Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

7.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

36.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.2K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "Differential association of Hedgehog pathway in development of cervical carcinoma and its chemo-tolerance" [Pathol. - Res. Pract. 248 (2023) 154696].

Pathology, research and practice·2026
Same author

Discovery, development, and characterization of potent and selective USP11 inhibitors.

Pharmacological research·2025
Same author

m6A eraser ALKBH5/treRNA1/DDX46 axis regulates BCR expression.

Neoplasia (New York, N.Y.)·2025
Same author

Differential association of hedgehog pathway in development of cervical carcinoma and its chemo-tolerance.

Pathology, research and practice·2023
Same author

Promoter methylation and enhanced SKP2 are associated with the downregulation of CDKN1C in cervical squamous cell carcinoma.

Cellular signalling·2023
Same author

Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.

Molecular medicine (Cambridge, Mass.)·2022

Related Experiment Video

Updated: Oct 4, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K

PARK2 regulates eIF4B-driven lymphomagenesis.

Bandish B Kapadia1,2, Anirban Roychowdhury1,2, Forum Kayastha1,2

  • 1Section of Hematology and Oncology, Medicine Service, McGuire Cancer Center, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia

Molecular Cancer Research : MCR
|February 2, 2022
PubMed
Summary
This summary is machine-generated.

High-risk diffuse large B-cell lymphoma (DLBCL) patients need new treatments. This study identifies PARK2 as a key regulator of protein translation, offering a potential new therapeutic target for lymphoma by modulating eIF4B stability.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K

Related Experiment Videos

Last Updated: Oct 4, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • High-risk diffuse large B-cell lymphoma (DLBCL) patients exhibit poor outcomes with standard R-CHOP therapy, highlighting an unmet need for novel treatments.
  • Dysregulation of protein translation initiation is implicated in lymphomagenesis.
  • While ubiquitination modulates translational initiation factors, the responsible E3-ligase remains unidentified.

Purpose of the Study:

  • To identify the E3-ligase responsible for ubiquitination of translational initiation factors.
  • To elucidate the role of PARK2 in protein translation regulation in lymphoma.
  • To investigate the upstream signaling pathways controlling PARK2 activity.

Main Methods:

  • Utilized complementary cellular models and clinical readouts.
  • Performed biochemical, mutational, and genetic studies.
  • Investigated the interaction between PARK2, eIF4B, and mTORC1 signaling.

Main Results:

  • Established that PARK2 ubiquitinates eIF4B, regulating protein translational activity.
  • Identified PARK2 as a substrate of mTORC1, which phosphorylates PARK2 at Ser127.
  • Demonstrated that mTORC1-mediated phosphorylation inhibits PARK2's ubiquitination activity, stabilizing eIF4B and enhancing protein translation.

Conclusions:

  • PARK2-mediated eIF4B ubiquitination acts as an anti-oncogenic inhibitor of protein translation, counteracted by mTORC1 signaling.
  • The FASN/mTOR-PARK2-eIF4B axis is implicated as a driver of enhanced oncogene expression in lymphomagenesis.
  • Targeting this axis may offer novel therapeutic strategies for high-risk DLBCL.